Skip to main content

What CBD And Grapefruit Have In Common When It Comes To Drug Interactions: Risks You Should Know

Hand holding bottle of CBD oil in pipette isolated

Getty

Interest in cannabidiol (CBD) is exploding. Now that major retailers are carrying CBD products, plus an enormous selection online, curiosity is only going up. But along with the enthusiasm, we also need healthy skepticism and caution. CBD research is still in the early stages, and marketing is predictably outpacing facts. Concerns about safety, among others, are getting lost in the hype.

Apart from a short list of possible side-effects, bigger concerns revolve around how CBD interacts with other drugs. Here’s a brief breakdown of possible risks if you’re thinking of trying it out.

What CBD and grapefruit have in common

You’re probably familiar with “grapefruit warnings” that appear on a variety of medications, or maybe your doctor or pharmacist has told you to avoid grapefruit or grapefruit juice when taking a particular med.

The reason for the warning is that grapefruit contains compounds called furanocoumarins that bind with and effectively neutralize enzymes in the gut (specifically CYP450 enzymes), which help break down and eliminate drugs. When these enzymes can’t do their job, too much of the drug enters the liver and flows unprocessed into the bloodstream. That elevates risk of having dangerously high levels of the drug in your system.

CBD is similar to grapefruit in that it also binds with those enzymes, but research suggests that it’s possibly even more potent because it binds in multiple parts of the gut and liver (grapefruit seems to mainly affect enzymes within the small intestine).  Once an enzyme has been inhibited, the effect isn’t immediately reversed. It can take days for enzyme function to return to baseline and start the process again.

In particular, research has found that CBD is a “potent inhibitor” of two enzymes (CYP3A4 and CYP2D6) that affect many common drugs, including antihistamines, benzodiazepines, certain antidepressants and statins.

What’s the risk?

The enzymes that both grapefruit and CBD inhibit are thought to break down a significant percentage of prescription medications, so the potential for problems could be high. 

A low dose of a med could become a high dose if it’s not properly broken down and eliminated. A high dose of a med could become a dangerously high dose, or even an overdose. Drugs with a narrow “therapeutic window” (they must stay within a certain blood-concentration range) are especially susceptible.

One of the big problems with CBD at the moment is we don’t really know yet which drugs are affected the most, and it’s difficult to identify exact levels of risk because the research has a lot of catching up to do after decades of science-blocking illegality. But since the compound appears to exert a similar effect as grapefruit, caution is needed.

What’s the best path forward?

At a minimum, the evidence at this point suggests that grapefruit warnings on medications carrying them should also apply to CBD. And it’s important to check with your doctor before taking CBD, especially if you’re taking other medications.  

The market for CBD products is predicted to pass $22 billion over the next four years, and that’s coming with the expected hurricane of fact-obscuring hype. With so much fanfare, it’s easy to ignore the fact that CBD is a potent compound that’s far from exhaustively understood. Research is uncovering upsides of taking it for a variety of conditions, and we’ll likely see more to come, but it’s also on us to recognize that this is an unfolding story and move forward with caution.

Original Article Source: https://www.forbes.com/sites/daviddisalvo/2019/06/30/what-cbd-and-grapefruit-have-in-common-when-it-comes-to-drug-interactions-risks-you-should-know/

Comments

Post a Comment

Popular posts from this blog

Mormon Church Faces Potential Lawsuit Over Medical Marijuana Opposition

Political committees concerned with marijuana law reform in four states have waged an information war over the past year, first to qualify cannabis initiatives for the ballot, and then to support or oppose those measures in the lead-up to last week’s midterm elections. In total, over  $12.9 million in cash and in-kind services was spent attempting to convince voters about these marijuana ballot measures. Now that voters have had their say, Marijuana Moment decided to calculate how much each “yes” and “no” vote cost the committees on either side of the debate. Our calculations are based on dollars raised and disclosed before the election, since final totals of actual expenditures won’t be available until December or January reports required in the states that voted on cannabis. Michigan In Michigan, where voters approved marijuana legalization , our calculations show that the two anti-legalization committees spent about $1.28 per “no” vote, as they raised $2.37 million for ...
Post a Comment
Read more

Mississippi Lawmakers Put Competing Medical Marijuana Measure On Ballot, Frustrating Advocates

A congressional committee approved two bills focused on marijuana and military veterans on Thursday. The action is the first markup of cannabis-related legislation on Capitol Hill this year. The bills approved by the House Veterans’ Affairs Committee are geared toward expanding access to medical cannabis for the veteran population and increasing research into the plant’s therapeutic benefits for conditions such as chronic pain and post-traumatic stress disorder (PTSD). The Veterans Equal Access Act, sponsored by Rep. Earl Blumenauer (D-OR), would allow doctors at the U.S. Department of Veterans Affairs (VA) to recommend medical marijuana to their patients in states where it’s legal. It was approved in a vote of 15-11. “Today was a monumental day for our veterans. We have been working for years to reform this counterproductive policy that forces veterans outside of the VA to receive legal medical cannabis treatment for chronic pain and PTSD,” Blumenauer said after the vote. “This is...
Post a Comment
Read more

NY Dem Chair Warns Against Passing Voter-Supported Marijuana Legalization Bill

The head of New York’s Democratic Party said on Thursday that if the state Senate votes on a marijuana legalization bill, his party’s lawmakers run the risk of alienating voters and losing reelection next year. Jay Jacobs, the state party chairman, claimed that several “far progressive” measures, including cannabis legalization, lack popularity in certain areas across the state such as Long Island and upstate New York. He cautioned lawmakers against putting the issue to a vote, arguing that voters would “throw us out of office.” “It could be the straw that breaks the camel’s back,” he told Newsday. Polling doesn’t support that conclusion, though. According to a March 2019 survey from Quinnipiac, 65 percent of New Yorkers are in favor of allowing adults to legally possess cannabis for personal use. That includes 63 percent of respondents in upstate New York and 65 percent of those living in the suburbs. Sixty-six percent of independents statewide also back ending marijuana prohibit...
Post a Comment
Read more